scispace - formally typeset
Open AccessJournal ArticleDOI

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

Jane Stevenson
- 01 Mar 2022 - 
- Vol. 399, Iss: 10328, pp 924-944
TLDR
A systematic review of the evidence for the duration of protection of COVID-19 vaccines against various clinical outcomes, and to assess changes in the rates of breakthrough infection caused by the delta variant with increasing time since vaccination was conducted as discussed by the authors .
About
This article is published in The Lancet.The article was published on 2022-03-01 and is currently open access. It has received 496 citations till now. The article focuses on the topics: Medicine & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California

TL;DR: In this article , the authors show that Omicron variant infections were associated with substantially reduced risk of progression to severe clinical outcomes relative to time-matched Delta (B.1.2) variant infections within a large, integrated healthcare system in Southern California.
Journal ArticleDOI

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway

Brian J. Willett, +672 more
- 07 Jul 2022 - 
TL;DR: In this article , the authors demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273.529.
Journal ArticleDOI

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022

TL;DR: This report uses data from CDC's national commercial laboratory seroprevalence study and the 2018 American Community Survey to examine U.S. trends in infection-induced SARS-CoV-2 serop revalence during September 2021-February 2022, by age group.
Journal ArticleDOI

Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden

TL;DR: In this article , the authors investigated the long-term protection from a previous infection (natural immunity) and whether natural immunity plus vaccination (hybrid immunity) was associated with additional protection.
Posted ContentDOI

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

TL;DR: During a period with mixed Delta and Omicron variant circulation, SARS-CoV-2 infections with presumed Omicrons variant infection were associated with substantially reduced risk of severe clinical endpoints and shorter durations of hospital stay.
References
More filters
Journal ArticleDOI

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.

TL;DR: Risk of Bias In Non-randomised Studies - of Interventions is developed, a new tool for evaluating risk of bias in estimates of the comparative effectiveness of interventions from studies that did not use randomisation to allocate units or clusters of individuals to comparison groups.
Journal ArticleDOI

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

TL;DR: It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.
Journal ArticleDOI

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.

TL;DR: In this paper, the overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system was evaluated.
Journal ArticleDOI

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.

TL;DR: In this paper, the authors investigated the effect of the booster dose on the rate of confirmed coronavirus 2019 disease (Covid-19) and the rates of severe illness.
Related Papers (5)